Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: Use of a novel noninferiority study design

Journal of Sexual Medicine

Volumn 3, Issue 3, 2006, Pages 492-503

  Morgentaler, Abraham ^a   Barada, James ^b   Niederberger, Craig ^c   Donatucci, Craig ^d   Garcia, Carmen S ^e   Natanegara, Fanni ^e   Ahuja, Sanjeev ^e   Wong, David G ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Center for Male Sexual Health   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Erectile dysfunction; Erectile function; Noninferiority trial; Tadalafil

Indexed keywords

SILDENAFIL; TADALAFIL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BACKACHE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; ETHNIC DIFFERENCE; ETHNIC GROUP; FLUSHING; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEADACHE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; POPULATION DISTRIBUTION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; SEXUAL FUNCTION; SIDE EFFECT; SPINAL CORD INJURY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 33645976900     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2006.00209.x     Document Type: Article

References (22)

1. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-13.
2. Morgentaler A. Clinical crossroads: A 66-year-old man with sexual dysfunction. JAMA 2004; 291: 2994-3003.
3. Sowers JR, Ferdinand KC, Bakris GL, Douglas JG. Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med 2002; 112: 24-6, 29-30, 33-4.
4. Gillum RF. Risk factors for stroke in blacks: A critical review. Am J Epidemiol 1999; 150: 1266-74.
5. Haffner SM, Morales PA, Hazuda HP, Stern MP. Levels of control of hypertension in Mexican-Americans and non-Hispanic whites. Hypertension 1993; 21: 83-8.
6. Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK. Risk factors for cardiovascular mortality in Mexican-Americans and non-Hispanic whites. Am J Epidemiol 1990; 131: 423-33.
7. Tate SK, Goldstein DB. Will tomorrow's medicines work for everyone? Nat Genet 2004; 36: S34-42.
8. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med, 2001; 344: 1351-7.
9. Tadalafil (prescribing information). Indianapolis, IN: Lilly ICOS LLC; 2003, updated 2005. Available at http://www.cialis.com/misc/tb00.jsp. Accessed 26 January, 2006.
10. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002; 168: 1332-6.
11. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, Shen W, Cordell WH. The efficacy and safety of tadalafil: An update. BJU Int 2004; 93: 1276-81.
12. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra ®) in clinical subpopulations: An update. Urology 2002; 60 (2B): 12-27.
13. Price D, Osterloh I, Gillies H. Viagra (sildenafil citrate) efficacy and tolerability in 25 double-blind, placebo-controlled, clinical trials in men with erectile dysfunction. Eur J Intern Med 2001; 12: 240.
14. Vardenafil (prescribing information). West Haven, CT: Bayer Pharmaceuticals Corporation, 2005. Available at http://www.levitra.com/. Accessed 26 January, 2006.
15. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-71.
16. Kulkarni PM, Meadows ES, Ahuja S, Muram D, Plouffe L Jr. Rationale for a non-inferiority clinical trial design focused on subpopulations. Curr Med Res Opin 2004; 20: 1641-7.
17. Points to consider on the choice of non-inferiority margin [online]. Available at: Http://www.emea.eu.int/pdfs/human/ewp/215899en.pdf (Accessed July 15, 2005).
18. Hwang IK, Morikawa T. Design issues in noninferiority/equivalence trials. Drug Inform J 1999; 33: 1205-18.
19. Landow L. Current issues in clinical trial design: Superiority versus equivalency studies. Anesthesiology 2000; 92: 1814-20.
20. Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials design concepts and issues - The encounters of academic consultants in statistics. Stat Med 2003; 22: 169-86.
21. Mulhall JP. Deciphering erectile dysfunction drug trials. J Urol 2003; 170: 353-8.
22. Young Y, Bennett C, Gilhooly P, Wessells H, Ramos DE. Efficacy and safety of sildenafil citrate (Viagra ®) in Black and Hispanic American men. Urology 2002; 60: 39-48.